a6af9174505509bc7100d4f20fa984c5 pmc_10090974.pdf 00b06ba1c9bc192e2aa72c9d39f4c886e4bacc87 pmc_10090974.pdf bf938115dd380252b2d37f66e6290d334fcf3a04335dfa517d2a4a76bc45b430 pmc_10090974.pdf Title: Innovating Therapies for Down Syndrome: An International Virtual Conference of the T21 Research Society Subject: Research focused on Down syndrome continued to gain momentum in the last several years and is advancing our understanding of how trisomy 21 (T21) modifies molecular and cellular processes. The Trisomy 21 Research Society (T21RS) is the premier scientific organization for researchers and clinicians studying Down syndrome. During the COVID pandemic, T21RS held its first virtual conference program, sponsored by the University of California at Irvine, on June 8–10, 2021 and brought together 342 scientists, families, and industry representatives from over 25 countries to share the latest discoveries on underlying cellular and molecular mechanisms of T21, cognitive and behavioral changes, and comorbidities associated with Down syndrome, including Alzheimer’s disease and Regression Disorder. Presentations of 91 cutting-edge abstracts reflecting neuroscience, neurology, model systems, psychology, biomarkers, and molecular and pharmacological therapeutic approaches demonstrate the compelling interest and continuing advancement toward innovating biomarkers and therapies aimed at ameliorating health conditions associated with T21. Author: Hamlett E.D.; Flores-Aguilar L.; Handen B.; Potier M.-C.; Granholm A.-C.; Sherman S.; Puig V.; Santoro J.D.; Carmona-Iragui M.; Rebillat A.-S.; Head E.; Strydom A.; Busciglio J. Creator: Adobe InDesign 18.0 (Windows) Producer: Adobe PDF Library 17.0 CreationDate: Mon Apr 3 08:18:39 2023 CEST ModDate: Thu Apr 6 08:10:35 2023 CEST Custom Metadata: no Metadata Stream: yes Tagged: no UserProperties: no Suspects: no Form: none JavaScript: no Pages: 12 Encrypted: no Page size: 595.276 x 793.701 pts Page rot: 0 File size: 384047 bytes Optimized: yes PDF version: 1.4 name type encoding emb sub uni object ID ------------------------------------ ----------------- ---------------- --- --- --- --------- ACMBZS+MyriadPro-Bold Type 1C WinAnsi yes yes yes 54 0 RUZUDK+MyriadPro-Regular Type 1C WinAnsi yes yes yes 55 0 CIKDBO+MinionPro-Regular Type 1C Custom yes yes yes 64 0 CIKDBO+MinionPro-Regular Type 1C WinAnsi yes yes yes 25 0 CIKDBO+MinionPro-Regular Type 1C WinAnsi yes yes yes 28 0 GEEWFG+MinionPro-It Type 1C WinAnsi yes yes yes 38 0 CIKDBO+MinionPro-Regular Type 1C WinAnsi yes yes yes 32 0 CIKDBO+MinionPro-Regular Type 1C WinAnsi yes yes yes 35 0 Jhove (Rel. 1.28.0, 2023-05-18) Date: 2024-05-07 04:30:39 CEST RepresentationInformation: pmc_10090974.pdf ReportingModule: PDF-hul, Rel. 1.12.4 (2023-03-16) LastModified: 2023-12-02 02:21:50 CET Size: 384047 Format: PDF Version: 1.4 Status: Well-Formed and valid SignatureMatches: PDF-hul MIMEtype: application/pdf Profile: Linearized PDF PDFMetadata: Objects: 81 FreeObjects: 1 IncrementalUpdates: 1 DocumentCatalog: ViewerPreferences: HideToolbar: false HideMenubar: false HideWindowUI: false FitWindow: false CenterWindow: false DisplayDocTitle: false NonFullScreenPageMode: UseNone Direction: L2R ViewArea: CropBox ViewClip: CropBox PrintArea: CropBox PageClip: CropBox PageLayout: SinglePage PageMode: UseThumbs Language: de-DE Info: Title: Innovating Therapies for Down Syndrome: An International Virtual Conference of the T21 Research Society Author: Hamlett E.D.; Flores-Aguilar L.; Handen B.; Potier M.-C.; Granholm A.-C.; Sherman S.; Puig V.; Santoro J.D.; Carmona-Iragui M.; Rebillat A.-S.; Head E.; Strydom A.; Busciglio J. Subject: Research focused on Down syndrome continued to gain momentum in the last several years and is advancing our understanding of how trisomy 21 (T21) modifies molecular and cellular processes. The Trisomy 21 Research Society (T21RS) is the premier scientific organization for researchers and clinicians studying Down syndrome. During the COVID pandemic, T21RS held its first virtual conference program, sponsored by the University of California at Irvine, on June 8 10, 2021 and brought together 342 scientists, families, and industry representatives from over 25 countries to share the latest discoveries on underlying cellular and molecular mechanisms of T21, cognitive and behavioral changes, and comorbidities associated with Down syndrome, including Alzheimer’s disease and Regression Disorder. Presentations of 91 cutting-edge abstracts reflecting neuroscience, neurology, model systems, psychology, biomarkers, and molecular and pharmacological therapeutic approaches demonstrate the compelling interest and continuing advancement toward innovating biomarkers and therapies aimed at ameliorating health conditions associated with T21. Creator: Adobe InDesign 18.0 (Windows) Producer: Adobe PDF Library 17.0 CreationDate: Mon Apr 03 08:18:39 CEST 2023 ModDate: Thu Apr 06 08:40:35 CEST 2023 ID: 0xf064898b3b4ed14995f68023bdde214e, 0x95d3ad2486d2d646b646e4db44eb700f Filters: FilterPipeline: FlateDecode Images: Image: NisoImageMetadata: FormatName: image/png ImageWidth: 882 ImageHeight: 506 ColorSpace: RGB BitsPerSample: 8 BitsPerSampleUnit: integer Filter: FlateDecode Intent: RelativeColorimetric Name: X Fonts: Type1: Font: BaseFont: CIKDBO+MinionPro-Regular FontSubset: true FirstChar: 30 LastChar: 244 FontDescriptor: FontName: CIKDBO+MinionPro-Regular Flags: Serif, Nonsymbolic FontBBox: -289, -360, 1684, 917 FontFile3: true EncodingDictionary: BaseEncoding: WinAnsiEncoding Differences: true ToUnicode: true Font: BaseFont: ACMBZS+MyriadPro-Bold FontSubset: true FirstChar: 32 LastChar: 121 FontDescriptor: FontName: ACMBZS+MyriadPro-Bold Flags: Nonsymbolic FontBBox: -92, -250, 1256, 897 FontFile3: true Encoding: WinAnsiEncoding ToUnicode: true Font: BaseFont: GEEWFG+MinionPro-It FontSubset: true FirstChar: 32 LastChar: 150 FontDescriptor: FontName: GEEWFG+MinionPro-It Flags: Serif, Nonsymbolic, Italic FontBBox: -201, -360, 1684, 919 FontFile3: true Encoding: WinAnsiEncoding ToUnicode: true Font: BaseFont: RUZUDK+MyriadPro-Regular FontSubset: true FirstChar: 32 LastChar: 244 FontDescriptor: FontName: RUZUDK+MyriadPro-Regular Flags: Nonsymbolic FontBBox: -46, -250, 1126, 881 FontFile3: true Encoding: WinAnsiEncoding ToUnicode: true XMP: 2023-04-03T08:18:39+02:00 2023-04-06T11:40:35+05:30 2023-04-06T11:40:35+05:30 Adobe InDesign 18.0 (Windows) uuid:95e1438d-639c-4a98-bc4f-09933dfa6ea5 adobe:docid:indd:a1ace0ee-97e8-11da-8f16-a6a04fdc746b xmp.id:cc4fe904-8c51-4a43-8d83-d4eb6a46bfc1 proof:pdf xmp.iid:c83f8dea-2480-fc43-80c8-af9dd3711e9e xmp.did:3f616560-c257-fd41-a33d-3a15ddf7b656 adobe:docid:indd:a1ace0ee-97e8-11da-8f16-a6a04fdc746b default converted from application/x-indesign to application/pdf Adobe InDesign 18.0 (Windows) / 2023-04-03T08:18:39+02:00 application/pdf Hamlett E.D.; Flores-Aguilar L.; Handen B.; Potier M.-C.; Granholm A.-C.; Sherman S.; Puig V.; Santoro J.D.; Carmona-Iragui M.; Rebillat A.-S.; Head E.; Strydom A.; Busciglio J. Innovating Therapies for Down Syndrome: An International Virtual Conference of the T21 Research Society This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Research focused on Down syndrome continued to gain momentum in the last several years and is advancing our understanding of how trisomy 21 (T21) modifies molecular and cellular processes. The Trisomy 21 Research Society (T21RS) is the premier scientific organization for researchers and clinicians studying Down syndrome. During the COVID pandemic, T21RS held its first virtual conference program, sponsored by the University of California at Irvine, on June 8–10, 2021 and brought together 342 scientists, families, and industry representatives from over 25 countries to share the latest discoveries on underlying cellular and molecular mechanisms of T21, cognitive and behavioral changes, and comorbidities associated with Down syndrome, including Alzheimer’s disease and Regression Disorder. Presentations of 91 cutting-edge abstracts reflecting neuroscience, neurology, model systems, psychology, biomarkers, and molecular and pharmacological therapeutic approaches demonstrate the compelling interest and continuing advancement toward innovating biomarkers and therapies aimed at ameliorating health conditions associated with T21. Down syndrome Intellectual disability Clinical research Preclinical research Biomarkers True https://www.karger.com/Article/FullText/526021#copyright Adobe PDF Library 17.0 False Pages: Page: Label: 89 Sequence: 1 Page: Label: 90 Sequence: 2 Page: Label: 91 Sequence: 3 Page: Label: 92 Sequence: 4 Page: Label: 93 Sequence: 5 Page: Label: 94 Sequence: 6 Page: Label: 95 Sequence: 7 Page: Label: 96 Sequence: 8 Page: Label: 97 Sequence: 9 Page: Label: 98 Sequence: 10 Page: Label: 99 Sequence: 11 Page: Label: 100 Sequence: 12 Checksum: cb586a47 Type: CRC32 Checksum: a6af9174505509bc7100d4f20fa984c5 Type: MD5 Checksum: 00b06ba1c9bc192e2aa72c9d39f4c886e4bacc87 Type: SHA-1 Checksum: bf938115dd380252b2d37f66e6290d334fcf3a04335dfa517d2a4a76bc45b430 Type: SHA-256